A 2.5 mg track has short direct data and real-world support for stable maintainers, but continuing tirzepatide has much stronger evidence than stopping. At week 112, stepping down to 5 mg preserved 16.6% weight loss versus 21.9% on the top dose and 9.9% on placebo
Figure 5: A) Time spent below range, time in range, time above high range, and time in tight range
Through its Nterminal domain, syn preferentially binds to lipid rafts, adopting an oligomerizationprone helical conformation [221, 224]
The idea is, this combination addresses skin appearance, tissue repair, and cellular recovery all at once
Not necessarily dangerous, but it needs medical oversight and close glucose monitoring